This article was originally published in The Tan Sheet
FDA reverses on OTC PPI fracture risk
You may also be interested in...
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
Prestige Brands gains from acquisitions
Colgate Buys Sanex Deodorants